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Summary:   
Background: B cells produce alloantibodies and activate alloreactive T cells, negatively 
affecting kidney transplant survival. In contrast, regulatory B cells are associated with 
transplant tolerance. There is an unmet need for immunotherapies that inhibit B cell effector 
function, including antibody secretion, whilst sparing regulators and minimising infection risk. 
B lymphocyte stimulator (BLyS) is a cytokine that promotes B cell activation, and has not 
previously been targeted in kidney transplant recipients. 
Aim: We sought to examine the safety and activity (the latter measured by a reduction in 
naïve B cells from baseline to week 24) of an anti-BLyS antibody, belimumab, in addition to 
standard of care immunosuppression in adult kidney transplant recipients. We utilised an 
experimental medicine study design with multiple secondary and exploratory endpoints to 
gain further insight into the effect of belimumab on the generation of de novo IgG and on the 
regulatory B cell compartment. 
Methods: We conducted a phase 2 double-blind randomised placebo-controlled trial of 
belimumab, in addition to standard of care immunosuppression (basiliximab, mycophenolate 
mofetil, tacrolimus and prednisolone), in adults aged 18-75 receiving a kidney transplant. 
Subjects were randomised at a single centre, Addenbrooke’s Hospital (UK), stratified 
according to receipt of a living or deceased donor organ. Within each stratum subjects were 
randomised by telephone in a 1:1 ratio to receive intravenous belimumab 10mg/kg or 
placebo (day 0, 14, 28 and every four weeks thereafter for a total of seven infusions). Co-
primary endpoints were safety and change in naïve B cells from baseline to Week 24. This 
trial has completed and is registered as ClinicalTrials.gov number NCT01536379 and 
EudraCT number 2011-006215-56.  
Findings: 28 kidney transplant recipients were randomised to belimumab (n=14) or placebo 
(n=14) treatment between 13th September 2013 and 8th February 2015. Twelve belimumab 
and 13 placebo patients were transplanted and went on to receive at least one dose of 
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belimumab/placebo (modified intention to treat (MITT) population). We observed similar rates 
of adverse events in belimumab and placebo groups, including serious infection (1/12 (8%) 
and 5/13 (38%) respectively during the six month on-treatment phase; 0/13 (0%) and 2/13 
(15%) during the six month post-treatment follow-up phase). There was one death in the on-
treatment phase in a patient in the placebo group. The co-primary endpoint of a reduction in 
naïve B cells from baseline to week 24 was not met; treatment with belimumab resulted in a 
trend towards, but not a statistically significant reduction in naïve B cells from baseline to 
week 24 (adjusted mean difference -34·4 cells/mm3 (95% confidence interval (CI) -109·5 to 
40·7)).  
Interpretation: Treatment with belimumab in addition to standard of care immunosuppression 
in low immunological risk renal transplant recipients was not associated with an adverse 
safety signal nor an increased risk of infection.  
Funding: GlaxoSmithKline 
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Panel: Research in context 
Evidence before this study 
Therapeutic agents that limit humoral alloimmunity in kidney transplant recipients are 
currently lacking.  B lymphocyte stimulator (BLyS; also known as BAFF) is a cytokine that 
promotes B cell survival, and we hypothesised that this pathway may represent a useful 
therapeutic target in transplantation. We searched PubMed using the terms ‘BAFF’ and 
‘kidney transplantation’ and ‘Clinical trial’ and Clinicaltrials.gov using the terms ‘kidney 
transplantation and ‘BAFF’ to establish the current clinical evidence-base in this area. Of the 
six studies identified in this search, only two included agents that targeted the BAFF/BLyS 
pathway, using monoclonal antibodies that bind BAFF/BLyS (tabalumab and belimumab), 
and only one of these was completed and published (Mujtaba et al. 2016). In fact, neither of 
these studies attempted BAFF/BLyS blockade in kidney transplant recipients. Both used an 
anti-BAFF/BLyS antibody as monotherapy in patients with end-stage kidney failure, with the 
aim of reducing pre-formed HLA antibodies to a level that permitted safe transplantation, but 
observed little effect. No trial to date has addressed the question of whether blockade of  
BAFF/BLyS could be a useful addition to current maintenance immunosuppressive agents 
following kidney transplantation.  
Added value of this study 
This study adds value to the existing evidence base by delivering the first data on the use of 
belimumab in kidney transplant recipients, showing no excess risk of infection and a 
reduction in naïve B cells, activated memory B cells, circulating plasmablasts, and kidney-
specific IgG. We also provide the first data on the impact of belimumab to reduce de novo 
IgG formation and increase regulatory B cell numbers in the peripheral blood. Our study 
informs clinical trials modulating the BLyS/BAFF axis in transplant recipients, and those 
using belimumab outside of the field of transplantation in systemic lupus erythematosus 
(SLE).  
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Implications of all the available evidence 
Our data suggest that belimumab may be a useful therapeutic strategy in standard 
immunological risk kidney transplant recipients to prevent de novo donor-specific antibody 
formation. The observed lowering of activated memory B cells and preformed IgG suggest an 
additional potential role in sensitised kidney transplant recipients or in those with antibody-
mediated rejection. Therefore, the use of belimumab warrants further study in these patient 
groups, in the context of larger randomised controlled trials.  
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Introduction 
Transplantation is the optimal renal replacement therapy for most patients with end-stage 
renal failure (ESRF). Current immunosuppressive regimens carry an increased risk of 
infection but limit T cell activation such that T cell mediated rejection (TCMR) occurs in less 
than 20% of kidney transplant recipients and is largely treatable. In contrast, there remain 
significant challenges in the field of humoral alloimmunity. De-novo donor-specific human 
leucocyte antigen (HLA)–specific immunoglobulin G (IgG) antibodies (DSA) and some non-
HLA IgG antibodies are associated with acute antibody-mediated rejection (ABMR) and 
allograft loss1-3. Furthermore, sensitised patients with pre-formed DSA have an elevated risk 
of acute and chronic ABMR, reducing graft survival4. B cells are not only the precursors of 
antibody-producing plasma cells, but act as antigen presenting cells and secrete pro-
inflammatory cytokines, including interleukin (IL)-6, that can activate T cells driving TCMR. 
Indeed, the presence of B cells in TCMR biopsies is a negative prognostic factor associated 
with steroid resistance5. Hence, there is an urgent unmet need in solid organ transplantation 
for immunotherapeutic strategies that target B cells and plasma cells6, ideally without 
increasing infectious complications. 
Efforts to inhibit pathological humoral immunity are complicated by the fact that B cells may 
also regulate immune responses via IL-10 production7,8. These regulatory B cells are 
enriched in transitional (CD24/CD38high)7 and memory (CD24high/CD27+) B cell compartments 
in humans8. Several lines of evidence suggest that regulatory B cells may be important in 
transplantation. Firstly, although a single dose of the anti-CD20 antibody rituximab at 
induction had no impact on transplant outcomes9,10, the use of a second dose within one to 
two weeks of transplantation was associated with TCMR in kidney transplant recipients11 and 
cardiac allograft vasculopathy12. Secondly, B cell transcripts and IL-10 producing B cells are 
increased in the peripheral blood of tolerant kidney transplant recipients13-15. Finally, kidney 
transplant recipients with a higher number of transitional B cells have reduced rejection16. 
Similarly, patients with a higher B cell IL-10:TNF ratio have a slower decline in transplant 
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function and reduced allograft loss17,18. In contrast, patients with rejection following ABO 
incompatible transplantation had fewer CD24high/CD27+ memory B cells19. Together, these 
data show that B cells can play both a positive and negative role in transplantation and 
highlight the need to identify immunosuppressants that preserve the immunoregulatory 
aspect of B cell function.  
B lymphocyte stimulator (BLyS; also known as BAFF) is a cytokine that enhances B cell 
survival and proliferation20 and contributes to the plasma cell niche21. The humanised anti-
BLyS IgG1 antibody, belimumab, is licenced for use in patients with SLE22, a disease 
characterised by high circulating BLyS23. In renal transplant recipients, elevated serum BLyS 
is associated with the development of de novo DSA24, high-titre HLA antibodies25, and an 
increased frequency of ABMR26. Experimental models suggest that BLyS neutralisation may 
be effective in preventing rejection27,28. BLyS inhibition, used as monotherapy, had little 
impact on HLA antibody titres in sensitised subjects on the transplant waiting list29,30, but to 
date, this axis has not been targeted in human transplant recipients.  
Currently, only 10% of compounds entering clinical trials reach patients as medicines. 
Experimental medicine seeks to improve this by ‘identify(ing) mechanisms of 
pathophysiology or disease, or … demonstrat(ing) proof-of-concept evidence of the validity 
and importance of new discoveries or treatments’ (UK Medical Research Council), thus 
providing detailed, mechanistic phenotypic data that precedes and informs late phase clinical 
development. 
We undertook a phase 2 randomised, double-blind, placebo-controlled experimental 
medicine trial of belimumab in addition to standard of care immunosuppression in renal 
transplant recipients to assess its safety and activity, as measured by a reduction in naïve B 
cells from baseline to week 24, and its effect on a number of exploratory endpoints. The use 
of belimumab was not associated with increased infection but led to a reduction in naïve B 
cells and activated memory B cells. The residual B cell compartment in belimumab-treated 
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subjects was skewed towards cells with a regulatory phenotype, with an increased capacity 
to produce IL-10 relative to IL-6. Following belimumab treatment, whole blood gene 
expression and protein microarray analysis indicated fewer circulating plasmablasts, reduced 
de novo IgG antibody formation and a reduction in kidney and endothelial cell-specific 
antibodies known to negatively impact graft outcome. In addition, belimumab treatment had a 
significant effect on the CD4 T cell transcriptome, with a marked reduction in cell cycle gene 
expression. Our data suggest that belimumab may be a useful therapeutic strategy to 
explore further in standard immunological risk kidney transplant recipients.  
METHODS 
STUDY DESIGN: 
In this phase IIA, randomised, double-blind, sponsor unblind study, subjects were recruited at 
a single UK transplant centre (Addenbrooke’s Hospital, Cambridge). The study was 
approved by the local Research Ethics Committee (East of England - Cambridge East). The 
study protocol is available at www.gsk-clinicalstudyregister.com 
STUDY PATIENTS: 
Patients aged 18 to 75 years receiving a kidney transplant were eligible for inclusion. 
Exclusion criteria included donor age <5 or >70 years, ABO blood type incompatibility, 0-0-0 
HLA mismatch, a positive T and/or B cell cross-match, and previous recipient exposure to B 
cell targeted therapy (full eligibility criteria are in study protocol, supplementary material). All 
patients provided written informed consent. 
RANDOMISATION AND MASKING: 
Subjects were stratified according to whether the recipient received a living or deceased 
donor organ. Within each stratum, subjects were randomised in a 1:1 ratio to either 
belimumab or placebo. Randomisation was performed by the investigators using the 
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GlaxoSmithKline telephone based Registration and Medication Ordering System (RAMOS). 
This was a double-blind study in which the investigator, patient and sponsor (with the 
exception of statistics personnel unblinded for interim/sample size re-estimation) were 
blinded to the treatment assignment. An unblinded pharmacist prepared the infusion 
according to the subject’s randomised treatment. 
PROCEDURES: 
Subjects received seven doses of belimumab 10mg/kg (GlaxoSmithKline, Rockville, MD, 
USA) or placebo (0.9% sodium chloride solution) by intravenous infusion over one hour at 
days 0, 14, 28 and then every four weeks to week 20, in addition to basiliximab (20mg IV 
days 0 and 3), tacrolimus (0.15mg/kg daily: target trough level 6-10μg/L first six months post 
transplantation, 5-8μg/L thereafter), mycophenolate mofetil (500mg twice daily) and 
prednisolone (20mg daily initially, weaning to 5mg daily in month 1-2). Patients received 
infection prophylaxis with nystatin (1st month), co-trimoxazole (months 1-6) and 
valganciclovir (months 1-6), and were followed for 12 months (see study protocol in 
supplementary material). 
For adverse event reporting the on-treatment phase commenced from the start of the first 
infusion of belimumab/placebo and ended 28 days after the last dose. The post-treatment 
phase began the following day. For other primary and secondary endpoints the on-treatment 
phase ended 35 days after the last dose to allow inclusion of the On-Trt Week 24 visit on day 
168 +/- 7 days. Details of visit windows can be found in the supplementary appendix.  
OUTCOMES: 
The first co-primary endpoint was safety assessed by: review of AEs and SAEs, classified 
using the Medical Dictionary for Regulatory Activities (MedDRA) and including AEs of special 
interest; and change from baseline and number of subjects outside the normal range for vital 
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signs and safety laboratory assessments, including immunoglobulin levels and white cell 
count.  
The second co-primary endpoint was change in naïve B cells from baseline to Week 24, a 
measure of functional BLyS neutralisation validated in patients with SLE31.  
Secondary and exploratory endpoints included pharmacodynamics, immunological 
biomarkers (e.g. regulatory B cells, assessment of peripheral blood transcriptional profiles, 
and non-HLA antibodies) and clinical endpoints. Full details of the secondary and exploratory 
endpoints can be found in the supplementary appendix and study protocol. 
B CELL STIMULATION ASSAYS:  
Frozen peripheral blood mononuclear cells (PBMC) were thawed and cultured in vitro with 
CpG DNA Oligodeoxynucleotides (100nM; Hycult Biotech) and CD40L (1µg/ml; R&D 
Systems). Phorbol 12-myristate 13-acetate (PMA) (50ng/ml; Sigma-Aldrich), ionomycin 
(500ng/ml; Sigma-Aldrich) and brefeldin A (5µg/ml; BioLegend) were added for the last five 
hours of culture and IL-6 and IL-10 quantified by flow cytometry.  
MICROARRAY ANALYSES:  
RNA was extracted from whole blood or from purified leukocyte subsets as described 
previously32, and hybridised to Human Gene ST 2.1 microarrays (Affymetrix). Microarray data 
are available in the ArrayExpress database (http://www.ebi.ac.uk/arrayexpress) under 
accession number E-MTAB-5906. 
Patient serum was hybridised to ProtoArray (Invitrogen) protein microarrays according to 
manufacturer’s instructions. 
Details of gene expression and protein array analyses are in the supplementary appendix. 
STATISTICAL ANALYSIS: 
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Primary analyses were undertaken using a pre-specified modified intention to treat 
population (MITT) including all patients randomised who received at least one infusion of 
belimumab/placebo. Secondary and exploratory biomarker outputs were undertaken using a 
pre-specified per protocol population (PP) that included all MITT subjects who received at 
least five infusions of belimumab/placebo, were followed up beyond week 24 and received 
no prohibited medications or plasma exchange (referred to as PP1 population in the study 
protocol). 
No formal statistical hypotheses were defined in the reporting and analysis plan (RAP). For 
the primary and secondary biomarker endpoints, a mixed model for repeated measures 
(MMRM) approach was used to produce adjusted mean differences between belimumab and 
placebo with corresponding 95% confidence intervals (details in supplementary appendix). 
For each of the primary and secondary endpoints, error diagnostics from the residuals were 
examined to ensure that the model did not depart from the assumptions underlying analysis 
of variance. If the assumptions were seriously violated, then non-parametric alternatives 
were performed as defined in the RAP. Non-parametric statistical analyses were performed 
on exploratory endpoints post hoc and these are marked as such. 
The target sample size of 20 evaluable subjects was informed by feasibility assessment but 
calculated with the aim of achieving a reduction in naïve B cell count from baseline to 24 
weeks. Assumptions for the sample size calculation are provided in the supplemental 
methods. 
Interim re-estimations of sample size were performed in November 2014 and February 2015. 
An extended safety review team, consisting at a minimum of a safety physician, a clinical 
development physician and a statistician, oversaw the study. 
Analyses were performed using SAS version 9.3 except for transcriptomic and protein 
microarray analyses, which were performed using R version 3.3.1. 
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ClinicalTrials.gov number NCT01536379; EudraCT number 2011-006215-56 
ROLE OF THE FUNDING SOURCE: 
The study was designed by the sponsor, GlaxoSmithKline, in close collaboration with 
principal investigators at Addenbrooke’s Hospital. Authors affiliated to GlaxoSmithKline, 
Addenbrooke’s Hospital and the University of Cambridge were jointly responsible for trial 
design, data collection, analysis and interpretation, report writing and the decision to submit 
the paper for publication. 
RESULTS 
Twenty-eight subjects were randomised to belimumab (n=14) or placebo (n=14) between 13th 
September 2013 and 8th February 2015. Twelve belimumab and 13 placebo patients went on 
to receive at least one dose of belimumab/placebo (Fig. 1) in addition to standard 
immunosuppression (Table S3). Baseline patient characteristics were comparable between 
groups (Table 1). Belimumab pharmacokinetic (PK) parameters were similar to those 
observed in SLE22 and were not affected by ESRF (Fig. S1A; Table S12). Belimumab 
effectively removed circulating BLyS, and levels remained suppressed up to week 12 post-
treatment, rebounding thereafter (Fig. S1B).  
The first co-primary endpoint was safety. We observed AE in 11/12 (92%) belimumab-treated 
subjects and 10/13 (77%) placebo-treated subjects during the 6 month on-treatment phase 
and 10/12 (83%) and 9/13 (69%) respectively during the 6 month post-treatment follow-up 
phase. AE occurring in more than one subject with a higher incidence in the belimumab 
group were diarrhoea, urinary tract infection, dizziness and vomiting (on treatment) and 
nasopharyngitis, urinary tract infection and type two diabetes (post treatment). For each 
event, the difference in frequency compared to placebo was no more than two subjects and 
not considered to represent a new safety signal. The number of patients experiencing 
serious AE were similar (5/12 (42%) of belimumab-treated and 7/13 (54%) of placebo-treated 
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subjects during the 6 month on-treatment phase and 2/12 (17%) and 2/13 (15%) respectively 
during the 6 month post-treatment follow-up phase). A key question we wished to address in 
this study was whether the use of belimumab in renal transplantation might be associated 
with an excess risk of infection. Belimumab has previously been used in patients with 
autoimmune diseases, in combination with steroids, and in some cases, an anti-proliferative 
agent (e.g., azathioprine, MMF or methotrexate)22. This is the first study to use belimumab 
with basiliximab induction and with triple maintenance immunosuppression (tacrolimus, MMF 
and prednisolone) in patients with ESRF at baseline, a condition known to be associated with 
a heightened susceptibility to infection33. Therefore, post-transplant infection was an 
important end-point, particularly given its association with an increased risk of rejection and 
allograft loss34. At 6 and 12 month follow-up, we observed no excess serious infection events 
in the belimumab group (1/12 (8%) and 5/13 (38%) in belimumab and placebo-treated 
patients respectively during the 6 month on-treatment phase and 0/13 (0%) and 2/13 (15%) 
respectively in the 6 month post-treatment follow-up phase). We also found no excess 
frequency of BK virus and cytomegalovirus (CMV) infection in belimumab-treated subjects 
(Table 2). There were no new diagnoses of malignancy in either group during the follow up 
period and one death, from a cardiovascular cause, in the placebo group (Table 2).  In 
summary, in this preliminary study, belimumab was not associated with an excess risk of 
serious infection or malignancy when used with standard transplant immunosuppression. 
BLyS is known to support the survival of transitional and naïve B cells20. Therefore, we 
assessed naïve B cell count as a co-primary endpoint. This co-primary endpoint of a 
reduction in naïve B cells from baseline to Week 24 was not met. When considering the 
MITT population, there was a trend towards a reduction, but no statistically significant 
difference in naïve B cells (adjusted mean difference naïve B cells from baseline to week 24 -
34·4 cells/mm3 (95% CI -109·5 to 40·7)) (Fig. 2A; Table S4). At later time points in the PP 
population that included all MITT subjects who received at least five infusions of 
belimumab/placebo, significant differences in naïve B cell count were observed; adjusted 
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mean difference naïve B cells from baseline to post treatment week 28 was -61.6 cells/mm3 
(95% CI -122.6 to -0·7) (Fig S1D; Table S4). A pre-specified non-parametric sensitivity 
analysis on the MITT population showed a greater reduction from baseline naïve B cell count 
with belimumab at post treatment week 12 and 28 (median difference at post treatment week 
28 -48.3 cells/mm3 (95% CI -144.7 to -13.0)) (Fig. S1E; Table S5). 
Biopsy proven TCMR (Banff grade I-III) occurs with a frequency of 15.3% in the 6 months 
post-transplant, in those receiving basiliximab-based induction therapy35. B cell depletion 
with the anti-CD20 antibody rituximab has been associated with increased TCMR11 and 
cardiac allograft vasculopathy12.  Since belimumab also depletes some B cell subsets, we 
sought to confirm that its use was not associated with an increase in alloimmune responses. 
The overall frequency of TCMR (including borderline episodes, Banff classification) was 
similar in belimumab (n=1/12 (16.7%)) and placebo-treated subjects (n=3/13 (23%), Table 1). 
One additional subject was randomised to the belimumab group and received a single dose 
at day 0 but was withdrawn from the study due to a positive B lymphocyte flow cytometry 
cross-match (an exclusion criterion), the results of which became available post-transplant. 
This subject subsequently developed Banff IIA TCMR rejection with features suspicious of 
early acute humoral rejection (day 6), with a further biopsy during treatment demonstrating 
grade II ABMR (day 34), both of which resolved following treatment with methylprednisolone 
(day 3-5), plasma exchange (day 8 & 38-52) and anti-thymocyte globulin (day 8-21) (details 
in supplementary appendix). In the context of pre-formed HLA antibodies and suboptimal 
induction immunosuppression their rejection episode was not unexpected; however given 
there was also one further episode of Banff grade IIA cellular rejection in the belimumab PP 
treatment group and only three Banff ‘borderline’ rejections in the placebo treated group (one 
was treated with corticosteroids), close monitoring for rejection episodes in larger studies will 
be required to better understand this observation. Overall, transplant function at one year, 
graft and patient survival were not negatively affected by the addition of belimumab to 
standard of care immunosuppression (Table 1 & 2). 
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Total B cell numbers were comparable throughout the study (Fig. S1C; Table S13). We 
observed fewer transitional (CD24brCD38brIgD+) B cells at post-treatment week 12 (adjusted 
mean difference -9156 cells/ml (95% CI -18307 to -6) (Fig. S1F; Table S14) with relative 
sparing of memory (CD20+CD27+) B cells (Fig. S1G; Table S15) such that the proportion of 
memory B cells was increased throughout the treatment and follow up period (maximal 
adjusted mean difference 25.7% (95% CI 16.0 to 35.5) at post-treatment week 12; post hoc 
analysis) (Fig. 2B, C; Table S7). In contrast to the effect of belimumab on the total memory B 
cell pool, activated memory (CD95+CD27+) B cells were decreased from post-treatment week 
12 to 28 (Fig. 2D, S1H; Table S16) (adjusted mean difference -14538.52 cells/ml (95% CI -
24875.4 to -4201.6) at post-treatment week 12). There was also a reduction in circulating 
CD19+CD27+CD38hi plasmablasts measured by flow cytometry at post-treatment week 12 
(adjusted mean difference -1055.5 count/ml (95% CI -1889.7 to -221.2; post hoc analysis) 
(Fig. S1I; Table S17). In order to further understand the impact of belimumab on B cell 
activation and differentiation into antibody-secreting cells, we assessed the whole blood 
transcriptome. Weighted gene co-expression network analysis identified a B cell gene 
expression module, identified as such based on the overrepresentation of genes annotated 
as part of the BCR signaling pathway in the Gene Ontology (Fig. S1L), with attenuated 
expression in belimumab-treated subjects (post hoc analysis; Fig. 2E). The most attenuated 
genes in this module coded for IgG, suggesting a strong effect on antibody-secreting cells 
and complementing our observation of fewer circulating plasmablasts and reduced de novo 
non-HLA antibody formation (described below).  
Eight study participants had anti-HLA antibodies (non donor-specific) at transplantation (3/12 
in the belimumab group and 5/13 in the placebo group, Table 1). We observed a variable 
reduction in pre-existing HLA class I and II antibody levels, but the small sample size 
precludes any definitive conclusions on the effect of belimumab (Fig. S2). Two patients 
recruited to the study developed de novo DSA during follow-up; both had been withdrawn 
following a single dose of belimumab for reasons unrelated to antibody development (Fig 
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S2C; see appendix for details).   
De novo HLA and non-HLA IgG autoantibodies can have a deleterious effect on allograft 
function2,3,36. In order to sensitively measure the ability of belimumab to inhibit the 
development of de novo IgG antibodies, we compared antibody binding to a human protein 
array in serum samples taken at time zero and week 24. This demonstrated that the addition 
of belimumab to standard of care immunosuppression significantly reduced de novo IgG 
antibody formation (median number new antibody specificities binding above threshold 55.5 
placebo vs 15.5 belimumab; post hoc analysis p=0.0474) (Fig. 2G; Table S8).  In addition to 
effects on de novo antibodies, we also observed an effect on pre-formed non-HLA antibodies 
that have been implicated in allograft damage; at week 24 we saw a trend towards reduced 
IgG specific for kidney antigens37 following belimumab treatment (median number antibodies 
binding kidney specific antigen above threshold 12.5 placebo vs 8.0 belimumab; post hoc 
analysis  p=0.0524 (Fig. 2H; Table S8); median mean protoarray signal 1307.3 placebo vs 
983.5 belimumab; post hoc analysis p=0.065 (Fig. S2D; Table S8), and a significant 
reduction in anti-EDIL3 (EGF-like repeats and discoidin I-like domains 3) antibodies at week 
24 (median of mean protoarray signal 353.6 placebo vs 261.9 belimumab; post hoc analysis 
p=0.0379) (Fig. S2E; Table S8), an endothelial cell-specific antibody associated with post-
transplant glomerulopathy36. The presence of antibodies to glial cell-derived neurotrophic 
factor (GDNF) at the time of transplantation has been associated with more severe chronic 
allograft injury (interstitial fibrosis and tubular atrophy) on 24 month biopsies3; we observed a 
reduction in the number of subjects with detectable anti-GDNF antibodies at week 24 
compared with time 0 in the belimumab group (6/8 and 2/8 at time 0 and 24 weeks 
respectively), in contrast to the placebo group (6/8 and 6/8 at time 0 and week 24 
respectively; post hoc analysis) (Fig. S2F). Together, these data emphasise that belimumab 
modulates a clinically important aspect of B cell function post-transplant.  
Transitional B cells have been associated with good outcomes in renal transplant, and this 
has been proposed to be due to their enrichment with IL-10 producing regulatory B cells15-18. 
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IL-10 producing B cells have also been identified within memory subsets8. We sought to 
address how belimumab treatment affects B cell cytokine production post-transplant. PBMC 
were stimulated ex vivo with CpG and CD40L, and B cell IL-10 and IL-6 production assessed 
(Fig. 3A, B; Table S9). Despite reductions in transitional B cells (Fig. S1F; Table S14), at 
week 12 post-treatment subjects receiving belimumab had a reduction in IL-6-producing B 
cells (median 42.62% placebo vs. 29.18% belimumab; post hoc analysis p=0.0379) and an 
increase in IL-10+ B cells (median 2.46% placebo vs. 4.56% belimumab; post hoc analysis 
p=0.0499) (Fig. 3A, B; Table S9), skewing the cytokine ratio toward a more regulatory profile 
compared with controls (median 0.059 placebo vs. 0.127 belimumab; post hoc analysis 
p=0.0070) (Fig. 3C). This skewing of cytokine production towards IL-10 was observed in both 
transitional and memory B-cell subsets (Fig. 3D; Table S10). To validate our findings and 
confirm that the effect of belimumab on B cell cytokine production was B cell intrinsic we 
cultured PBMC enriched for memory B cells from healthy controls with BLyS in the presence 
or absence of belimumab. This demonstrated that BLyS stimulation significantly decreased B 
cell IL-10 relative to IL-6 (mean % change from baseline with 100ng/ml BLyS -22.90% 
(95%CI -36.52, -9.28); post hoc analysis p=0.0029) and was abrogated by the addition of 
belimumab (mean % change from baseline with 100ng/ml BLyS + 15nM belimumab 0.63% 
(95%CI -18.28, 19.54); post hoc analysis p=0.9377) (Fig. 3E; Table S11) providing new 
insights for Breg biology.  
We also investigated whether T cell activation was altered by belimumab treatment, since B 
cells are potent antigen presenting cells and IL-6 may augment T cell activation38 whilst IL-10 
can regulate T cell responses39. There was no difference in the number of circulating T cells 
by treatment (Fig. S1J-K); Table S18-19) but transcriptomic analysis of purified circulating 
CD4 T cells revealed reduced expression of cell-cycle genes in belimumab-treated subjects 
(post hoc analysis; Fig. 3F, Table S2) suggesting that BLyS neutralisation may also inhibit T 
cell proliferation. 
DISCUSSION 
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A key goal of this study was to determine the safety profile of belimumab in combination with 
standard transplant immunosuppression. Although belimumab has previously been used in 
patients with SLE with renal involvement, it has not been used in those with established 
ESRF, which in itself confers an increased risk of infection33. Despite this, and a significantly 
greater burden of concomitant immunosuppression than used previously, we observed no 
excess infections with the addition of belimumab. Observed AEs were consistent with that 
expected for the underlying population, concurrent medications and known safety profile of 
belimumab.  
The co-primary endpoint of a reduction in naïve B cells from baseline to week 24 was not 
met in the MITT population, due to the impact of subjects that received only one dose of 
belimumab on a group with limited sample size. However, sensitivity and pre-specified 
analyses performed on the PP population that included subjects who received at least five 
doses of belimumab/placebo, confirmed that belimumab did have a significant biological 
effect, greatest at post treatment week 12. Sample size calculation relied on data from 
studies of belimumab in SLE; it is likely that the more intense immunosuppression given in 
the immediate post-transplant period masked earlier differences.  
Although the co-primary endpoint of a reduction in naïve B cells from baseline to week 24 
was not met, data from secondary and mechanistic end-points suggest but do not definitely 
prove, potential beneficial effects of belimumab post-transplant. Despite depletion by 
belimumab of the transitional B cell subset known to contain regulatory B cells, remaining B 
cells after belimumab treatment demonstrated an increased capacity to produce the 
immunoregulatory cytokine IL-10 relative to IL-6. Since B cells are the major source of IL-6 in 
secondary lymphoid organs40, this observation is significant and of potential clinical benefit in 
transplantation: IL-6 promotes B cell differentiation into antibody-forming plasma cells, 
contributes to the plasma cell niche41, enhances T follicular helper cell differentiation (critical 
for the germinal centre response),  and inhibits the generation of regulatory T cells38.  Indeed, 
an IL-6R antagonist has been used to treat patients with chronic ABMR42.  
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We present flow cytometry, transcriptomic and protein microarray data suggesting that BLyS 
neutralisation reduced antibody-forming cells and resulted in a lower incidence of de novo 
non-HLA autoantibody formation post-transplant. In particular, observed trends in kidney and 
endothelial specific IgG raise the possibility of improved longer-term transplant 
outcomes2,3,36. Our study also highlights the role of BLyS in memory B cell activation. 
Belimumab-treated subjects had fewer circulating activated (CD95+) memory B cells, 
suggesting a rationale for using belimumab as a longer-term adjuvant in sensitised transplant 
subjects with pre-existing donor-specific memory B cells, in addition to lymphocyte depletion 
and antibody removal. This strategy is currently being studied in a recently established 
clinical trial using belimumab in combination with bortezomib, plasma exchange and 
rituximab as a desensitisation therapy (ClinicalTrials.gov Identifier: NCT02500251). Finally, a 
decrease in T cell proliferation markers demonstrates the potential for belimumab to 
modulate both cellular and humoral alloimmunity. 
Our study has several limitations; the sample size was not powered for clinical endpoints, 
limiting the broader interpretation of our findings. Early phase studies with modest numbers 
cannot provide definitive data on safety; with this caveat we report no major adverse safety 
signal. Despite modest numbers, we were able to implement a range of assays measuring 
both clinical and immunological parameters so that our major findings are backed by multiple 
independent readouts, for example flow cytometry, transcriptional differences and antibody 
array, which together support robust and clinically useful effects on the B cell compartment 
post-transplant. 
The study population (standard immunological risk transplant recipients without DSA) was 
selected in light of previous studies in SLE showing a significant effect of belimumab on 
naïve B cells; we therefore hypothesised that the depletion and inhibition of naïve B cells 
may prevent the development of de novo HLA antibodies in low risk patients. However, these 
patients have a low risk of developing DSA (around 10% per annum) and a trial powered to 
detect a difference would need several thousand patients, unfeasible for a Phase 2 
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experimental medicine study. The transplant community has acknowledged that the unmet 
need for novel effective therapies for ABMR and to improve long-term graft outcomes may be 
best addressed through non-traditional trial designs that include surrogate endpoints43. 
Although our study did not include sensitised subjects at greatest risk of ABMR and graft 
loss, the occurrence of ABMR in the sensitised subject that was inadvertently included in the 
study provides valuable information for the design of future trials in this area, suggesting that 
such patients may well need antibody removal and pan-lymphocyte depletion in addition to 
belimumab. Further studies will be required to evaluate the safety and efficacy of belimumab 
alongside lymphocyte depleting treatments including thymoglobulin or alemtuzumab, agents 
that previously associated with an increase in serum BLyS44. Whether belimumab would 
have the same pro-regulatory effect on the reconstituted B cell pool when used in 
combination with lymphocyte-depletion remains to be determined. An observed rebound in 
serum BLyS following cessation of belimumab raises the question of whether belimumab 
should be administered for a more extended period post-transplant, with graduated 
discontinuation alongside monitoring of serum BLyS.  
This study exemplifies an experimental medicine approach and suggests potential efficacy of 
belimumab as an immunomodulatory agent in transplantation that can limit new antibody 
formation, providing a useful platform to support design of future clinical studies to explore 
the further use of belimumab in renal transplantation. In addition, our study provides new 
insights into BLyS biology and the mechanism of action of belimumab, including novel 
preliminary data on its effect on the regulatory B cell compartment and autoantibody 
production, which are also of relevance in autoimmunity.  
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Table 1. Baseline Demographics and Clinical Outcomes. 
    
Placebo (n=13) 
Belimumab 
10mg/kg (n=12)   
  Baseline demographic data, n 13 12   
  Age (years), Mean (SD) 51.0 (14.0) 54.3 (11.0)   
  Range 24-73 32-72   
  Sex, n (%)        
  - Female 4 (31) 7 (58)   
  - Male 9 (69)  5 (42)    
  Race, n (%)          
  - White/Caucasian 12 (92)   11 (92)   
  - Asian 1 (8)   1 (8)   
  Mean number (SD) of HLA-A/B/DR mismatches   
  - HLA-A 1.7 (0.5) 1.8 (0.5)   
  - HLA-B 0.9 (0.6) 1.1 (0.3)   
  - HLA-DR 0.6 (0.5) 0.8 (0.6)   
  Number of previous kidney transplants, n (%)    
  - 0 11 (85) 11 (92)   
  - 1 2 (15)  1 (8)   
  Pre-transplant renal replacement modality, n (%)   
  - None 3 (23) 2 (17)   
  - Haemodialysis 7 (54) 7 (58)   
  - Peritoneal dialysis 3 (23) 3 (25)   
  HLA antibody at baseline (MFI>2000)3, n (%)   
  - Non-DSA 5 (38) 3 (25)   
  - DSA 2 0 1 (8)   
  Donor type, n (%)       
  - Living 3 (23) 4 (33)   
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  - Donation after circulatory death 7 (54) 5 (42)   
  - Donation after brain death 3 (23) 3 (25)   
  Donor age (years)       
  Mean (SD) 52.9 (8.8) 58.3 (8.1)   
  Range 37-68 47-69   
  Donor creatinine-last value prior to transplant (μmol/L)   
  Mean (SD) 64.8 (17.5) 84.3 (30.7)   
  Median (Min, Max) 66.0 (37-92) 78.0 (51-167)   
  Clinical outcome data1, n 8   8   
  Acute transplant rejection by week 522, n (%)   
  - Borderline, not treated 2 (25) 0   
  - Borderline, treated 1 (12.5) 0   
  - Type IIa, treated 0 1 (12.5)   
  Cumulative HLA class I (MFI >500)3 Sub 22 Sub 28 Sub 8 Sub 27   
  Before treatment 39612 20046 127392 4894   
  On treatment Wk 2 24658 14731 56453 4493   
  On treatment Wk 4 26129 21466 33810 3438   
  On treatment Wk 8 28930 19528 34420 4632   
  On treatment Wk 12 26709 26500 25985 6320   
  On treatment Wk 24 23152 18376 26491 8103   
  Post treatment Wk 28 19204 18892 24607 4349   
  
Cumulative HLA class II (MFI 
>500)3 Sub 4   Sub 1     
  Before treatment 2382   16009     
  On treatment Wk 2 916   9305     
  On treatment Wk 4 1211   12346     
  On treatment Wk 8 768   12553     
  On treatment Wk 12 606   10540     
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  On treatment Wk 24 577   13408     
  Post treatment Wk 28 785   9075     
  Graft survival, n (%) 8 (100) 8 (100)   
  Creatinine at 52 weeks (μmol/L)   
  Mean (SD) 142.5 (65.7) 110.6 (43.6)   
  Median (Min, Max) 114 (86-282) 94 (68-201)   
  eGFR at 52 weeks (ml/min/1.73m2),        
  Mean (SD) 53.00 (22.10) 57.42 (15.08)   
  Median (Min, Max) 
54.03 (20.41-
86.63) 
56.77 (30.25-
81.93)   
              
1Clinical outcome data described for the per protocol population. 
2Acute rejection was defined on biopsy according to Banff 2009 criteria: Acute antibody 
mediated rejection (Grade I, II or III) or acute T cell mediated rejection (Borderline, Type IA, 
Type IB, Type IIA, Type IIB, Type III). An additional subject randomised to belimumab had a 
positive pre-transplant MHC class II flow crossmatch (fulfilling an exclusion criterion but 
unknown at the time of enrolment and transplant). They experienced Type IIA acute cellular 
rejection (day 6) and grade II antibody mediated rejection (day 34). They were withdrawn 
once the crossmatch was recognised following a single dose of belimumab. 
3A cut-off of MFI>2000 was used to define preformed HLA antibody at baseline, since this is 
the threshold for clinical significance determined by the tissue-typing laboratory. Cumulative 
HLA class I and class II MFI calculated by summing the normalised MFI values for any single 
antigen bead with a value above the level of detection (500). An additional subject in the 
belimumab group underwent adoptive transfer of donor HLA-specific allosensitization 
following kidney transplantation from a highly sensitized donor. 
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SD standard deviation, n number of subjects, HLA human leukocyte antigen, MFI mean 
fluorescence intensity measured by Luminex assay, DSA Donor specific antibody, Min 
minimum, Max maximum, and eGFR estimated glomerular filtration rate. 
Table 2. Safety Findings During On-treatment and Post-treatment Phases, by Treatment 
Group. 
  On treatment 1 Post-treatment  
  Number (%) Subjects  Number (%) Subjects  
  
Placebo  Belimumab  Placebo  Belimumab  
(n=13)  (n=12)  (n=13)  (n=12)  
Any adverse event (AE)   10 (77)  11 (92)  9 (69)  10 (83)  
Any serious AE (SAE)  7 (54)  5 (42)  2 (15)  2 (17)  
Any severe AE  6 (46)  8 (67)  3 (23)  3 (25)  
Deaths 2 1 (8)  0 0 0 
Most common AE 3              
- Leukopenia 4 (31)  4 (33)  3 (23)  3 (25)  
- Diarrhoea  3 (23)  5 (42)  1 (8)  1 (8)  
- Urinary tract infection 4 3 (23) 4 (33) 1 (8) 2 (17) 
- Anaemia 5 4 (31)  3 (25)  0 1 (8) 
- Lower respiratory tract infection 6 2 (15)  2 (17)  2 (15)  0 
- Dyspepsia7 2 (15)  2 (17)  2 (15)  0 
- Nasopharyngitis  2 (15)  1 (8)  1 (8)  2 (17)  
- Alanine aminotransferase increased  2 (15)  2 (17)  0 0 
- Diabetes Mellitus8  1 (8)  1 (8)  0 2 (17)  
- Endoscopic evidence upper GI inflammation9 2 (15)  1 (8)  0 0 
- Dizziness  0 2 (17)  0 1 (8)  
- Vomiting  0 2 (17)  0 0 
Infections              
- All  7 (54)  5 (42)  8 (62)  6 (50)  
- Serious infections (n≥1)  5 (38) 1 (8) 2 (15) 0 
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- Severe infections (n≥1)  5 (38)  2 (17)  3 (23)  0 
- Opportunistic infections  3 (23)  2 (17)  3 (23)  3 (25)  
    - BK viraemia 2 (15)  1 (8)  1 (8)  1 (8)  
    - BK viraemia-associated nephropathy  0 1 (8)  1 (8)  0 
    - Cytomegalovirus (CMV) viraemia10 1 (8)  0 1 (8)  2 (17)  
Malignant neoplasm  0 0 0 0 
Depression/Suicide/Self injury  0 0 0 0 
Post infusion systemic reaction11 0 1 (8)  NA  NA  
Recurrence of focal segmental 
glomerulonephritis12 1 (8)  1 (8)  0 0 
Hypogammaglobulinemia of grade ≥3 
(<4.0g/L) 2 (15)  3 (25)  0 0 
 
1The on-treatment phase commences from the start of the first infusion of randomised study 
drug and ends 28 days after the last dose. The post-treatment phase begins the following 
day. 
2Death due to fatal myocardial infarction and acute cardiac failure. 
3Includes all AEs (by grouped MedDRA preferred terms) occurring in more than one subject 
during the study not including opportunistic infections (listed separately), ordered by overall 
frequency. 
4Grouped preferred terms include urinary tract infection, Escherichia urinary tract infection, 
urinary tract infection enterococcal and urosepsis. 
5Grouped preferred terms include anaemia, anaemia vitamin B12 deficiency and iron 
deficiency anaemia. 
6Grouped preferred terms include pneumonia and lower respiratory tract infection. 
7Grouped preferred terms include dyspepsia and gastrooesophageal reflux disease. 
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8Grouped preferred terms include diabetes mellitus and type two diabetes mellitus; one post 
treatment AE was worsening of diabetes, onset on treatment, in context of steroids for SAE 
(colitis) 
9Grouped preferred terms include oesophagitis, duodenal ulcer, duodenitis and ulcerative 
gastritis. 
10Grouped preferred terms include cytomegalovirus test positive, cytomegalovirus viraemia, 
culture positive (verbatim term CMV). 
11The infusion reaction reported was mild, settled spontaneously and did not recur on 
subsequent infusions. 
12Grouped preferred terms include focal segmental glomerulosclerosis (FSGS) and 
glomerulonephritis (recurrence of FSGS verbatim term). NA denotes not applicable.  
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Figure 1. Enrolment, Randomisation and Follow-up. 
The randomised treatment was given in addition to standard immunosuppression consisting 
of basiliximab, mycophenolate mofetil, tacrolimus and corticosteroids (see methods for full 
details).  
1260 at Addenbrooke’s Hospital, Cambridge (28 randomised); 43 at Guy's and St Thomas’ 
NHS Foundation Trust, London (0 randomised). 
2Reasons for not meeting inclusion criteria shown in Supplementary Table 1. Logistical 
reasons included unavailability of study staff or randomised study drug, insufficient time for 
consent and recipient resident out of region.  
3The pre-specified per protocol (PP) population used for biomarker and clinical endpoint 
analysis consisted of all subjects in the modified intention to treat (MITT) population who 
received at least five infusions of belimumab/placebo, no prohibited medications or plasma 
exchange and at least 24 weeks follow-up.  
FSGS Focal Segmental Glomerulosclerosis, SAE Serious Adverse Event 
 
Figure 2. Belimumab Affects Naïve B Cells, Activated Memory B Cells and Circulating 
Plasmablasts, and Reduces Allo/Auto-antibody Generation. 
Panel A shows the adjusted mean (95% CI) change from baseline in naïve (CD20+CD27-) B 
cell count (cells/mm3), by visit and treatment.  
Panel B is a radar plot summarising the median difference from baseline to week 24 
compared to baseline (i.e. percentage at week 24 – percentage at week 0) for the labelled B 
cell populations by belimumab or placebo, where each B-cell population is expressed as a 
percentage of total B cells.  
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Panel C shows memory (CD20+CD27+) B cells expressed as a percentage of B cells by visit 
and treatment group.  
Panel D shows the relationship between memory B cell count (cells/mm3) and activated 
memory B cell (CD95+CD27+) percentage at the post treatment week 12 timepoint for 
individual subjects labelled by treatment group.  
Panel E shows expression (arbitrary units) of a B cell whole blood gene expression module 
by treatment group at baseline, end of on-treatment phase (Week 24) and end of follow-up 
(Week 52). Horizontal lines correspond to median and interquartile ranges.  
Panel F shows a heat map of differential gene expression (belimumab versus placebo 
groups) for genes in the B cell module at baseline, week 24 and week 52. Genes are ordered 
by fold-change at week 24 and immunoglobulin-coding transcripts are highlighted. Colour 
corresponds to log2-fold change, with blue indicating higher expression in the placebo group 
(Placebo) relative to the belimumab group (Belimumab).  
Panel G shows the number of unique ProtoArray antigen specificities with significant 
antibody binding at Week 24 but not at baseline. Horizontal lines on boxplot (left) correspond 
to median and interquartile ranges. Ordered individual participant data are also shown (right), 
with participants coloured by treatment group. The Wilcoxon rank-sum test was used to 
compare the belimumab treatment group (BEL) and placebo treatment group (PBO); * 
denotes p<0.05.  
Panel H shows the number of kidney-specific unique ProtoArray antigen specificities (as 
defined in 37) with significant antibody binding at Week 24. Horizontal lines on boxplot (left) 
correspond to median and interquartile ranges. Ordered individual participant data are also 
shown (right), with participants coloured by treatment group. The Wilcoxon rank-sum test 
was used to compare the belimumab treatment group (BEL) and placebo treatment group 
(PBO); exact p value displayed. 
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Panel A uses the MITT population. Panels B, C, D, G and H use the PP population. Panels E 
and F use the MITT population for baseline and the PP population thereafter. C shows raw 
values at baseline for comparison and adjusted mean estimate with 95% confidence intervals 
at subsequent timepoints. Adjusted mean estimates and 95% confidence intervals are 
obtained from MMRM model, with fixed categorical effects of treatment, visit, donor type and 
treatment-by-visit interaction and fixed continuous covariates of baseline and baseline-by-
visit interaction. A compound symmetry variance structure was used to model the within-
patient errors, shared across treatments. # indicates that the 95% confidence interval of the 
treatment difference does not include zero. D shows data for individual PP subjects labelled 
by treatment group. Panels B, C, D, E, F, G and H represent analyses performed post hoc. 
 
Figure 3. Memory B Cell IL-10/IL-6 Ratio is BLyS Dependent. Belimumab Treatment 
Increases Regulatory B Cells and is Associated with Reduced T cell Proliferation. 
Peripheral blood mononuclear cells (PBMC) were stimulated ex vivo for 5 hours and 
intracellular cytokine production quantified by flow cytometry (Panel A-D). Individual data 
points represent individual subjects with horizontal lines signifying the median for each 
treatment group. Wilcoxon rank-sum tests were performed to compare samples by treatment 
and visit.   
Panel A shows representative flow cytometry plots for IL-6 (upper) and the percentage of 
CD19+ B cells expressing IL-6 (lower).  
Panel B shows representative flow cytometry plots for IL-10 (upper) and the percentage of 
CD19+ B cells expressing IL-10 by treatment group and timepoint (lower).  
Panel C shows the calculated ratio of IL-10/IL-6 with higher values indicating a more anti-
inflammatory cytokine milieu.  
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Panel D shows the IL-10/IL-6 ratio for individual subsets of naïve (CD27-), transitional 
(CD24hiCD38hiIgD+), CD24+CD27+ memory, switched memory (CD27+IgD-), and non 
switched memory (CD27+IgD+) B cells at post treatment Wk 12.  
Panel E shows the mean IL-10/IL-6 ratio (relative to 0ng/mL BLyS) with 95% confidence 
intervals for PBMC from healthy volunteers enriched for CD27+ memory B cells and 
stimulated for 48 hours with increasing quantities of BLyS. In the presence of increasing 
quantities of BLyS a more inflammatory cytokine milieu was observed. This change was 
blocked by the addition of belimumab. N, number of healthy volunteers tested for each 
experimental condition. T-tests were performed to determine whether the mean percentage 
changes from baseline differed significantly from 0 for each experimental condition. 
Panel F shows a heatmap of differential gene expression in circulating CD4+ T-cells for the 
most downregulated genes at week 24 in the belimumab group relative to the placebo group, 
with genes ordered by unsupervised hierarchical clustering. Genes annotated to the cell-
cycle (GO:0007049) are highlighted. Colour corresponds to log2-fold change, with blue 
indicating higher expression in the placebo group (Placebo) relative to the belimumab group 
(Belimumab). 
Panels A-D use the PP population and Panel F uses the MITT population for baseline and 
PP population thereafter. P-values in Panels A-D were calculated using Wilcoxon rank-sum 
tests and indicated where significant; in all other cases the values are not statistically 
significantly different. P-values in Panel E were calculated using Student’s t-test. * p<0.05, ** 
p<0.01, *** p<0.001, NS not significant (p≥0.05). All analyses were performed post hoc. 
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 Figure1: Enrolment, Randomisation and Follow-up.
303 patients were assessed for 
eligibility1 
275 were excluded2  
•  123 did not meet inclusion criteria  
•  46 refused consent  
•  106 had logistical reasons
1
 
 
12 included in the primary analysis (MITT 
population) 
2 excluded because never received study drug 
8 included in biomarker and clinical endpoint 
analysis3 
14 were allocated to belimumab 10mg/kg  
•  12 received at least one dose  
•  2 did not receive allocated intervention 
(transplantation did not occur) 
14 were allocated to placebo  
•  13 received at least one dose  
•   1 did not receive allocated intervention 
(transplantation did not occur)  
13 included in the primary analysis (MITT 
population) 
1 excluded because never received study drug 
8 included in biomarker and clinical endpoint 
analysis3 
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Analysis 
Follow-Up 
28 randomised  
Enrollment
9 completed follow-up 
• 1 received less than 5 doses of study drug 
 
3 discontinued intervention  
•  Positive crossmatch available post Tx/SAE 
of rejection (n=1) 
•  SAE of recurrent FSGS; unblinding required 
to guide further treatment (n=1) 
•  Withdrew consent (n=1) 
 
11 completed follow-up 
•  1 had SAE of recurrent FSGS requiring 
plasma exchange 
•  2 received less than 5 doses of study drug 
 
2 discontinued intervention  
•  Death (n=1) 
•  Withdrew consent (n=1) 
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Figure 2. Belimumab Affects Naïve B Cells, Activated Memory B Cells and Circulating Plasmablasts, 
and Reduces Allo/Auto-antibody Generation.
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Figure 3. Memory B cell IL-10/IL-6 Ratio is BLyS Dependent. Belimumab Treatment Increases 
Regulatory B cells and is Associated with Reduced T cell Proliferation.
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